This resource is only available for ASCRS Members. Please log in using the teal "Login" button in the top right-hand corner to log in.
To compare Femto CXL with conventional, and prove deeper crosslinking better dampens ectasia progression & study its long-term outcomes
A non-randomised comparative clinical trial followed by single arm longitudinal analysis of Femto CXL group. In phase 1 Femto CXL (FC),creation of a bed, 8.5mm dia., 140 mic. deep, into which riboflavin was infused & subsequent UVA) was compared with conventional(CC). Vision, CCT, K max, astigmatism, OCT derived demarcation line (DL) were analyzed at 1year.In phase 2 FC was followed at 2 years.
In Phase1 (25 FC, 21 CC) UCVA improved in FC (0.64 +/-0.25), BCVA was similar CCT maintained in FC (474+/- 37.5 mic), reduced by 25 mic. (p<0.05) in CC. Astigmatism reduced in FC by 0.25D, increased by 0.27D in CC. DL in FC (393+/- 34.1 mic) Vs (243 +/- 15.9 mic) in CC. In Phase2 (24 FC), CCT(470+/- 36.53 mic), UCVA (0.61 +/-0.26), BCVA (0.14 +/-0.13), Astigmatism (2.84 +/- 1.23D) and KMax (47.6 +/- 2.28D) were maintained.
Crosslinking deeper than 250 microns could be achieved with femto assisted CXL than with conventional CXL and Femto-CXL treated eyes remained stable with no progression after 2 years.